Angiogenesis has not yet been validated as a therapeutic target in advanced urothelial carcinoma. However, a recent phase II trial has suggested that ramucirumab - a vascular endothelial growth factor (VEGF) receptor-2 antibody - combined with second-line docetaxel, might be beneficial.
展开▼
